CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Sep 04, 2003
This stock and Merk are not acting well. Some talk of downward earning revisions. Seeing pressures on high drug prices.
Photo of Ross HealyRoss HealyUnlock Rating
$30.60

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Sep 03, 2003
Has a big portfolio of drugs. Buying under $30. Trading at a significant discount to the market. Profit margins are shrinking because of government pressures because of deficits. Competition from generic drugs.
Photo of Brad WillockBrad Willock
Owned
Unlock Rating
$30.88

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 29, 2003
In a decline in the charts.
Photo of David ChapmanDavid Chapman
No
Unlock Rating
$29.92

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 27, 2003
Likes the company at these levels. Their recent merger will create growth. There should be 13/14% growth in earnings over the next couple of years.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$29.91

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 22, 2003
Pharmaceutical stocks are defensive in nature.In this environment, nobody's buying them.Will be dead money in the short term.The strongest of the drug companies and the deepest pipeline.A good price to buy out for the long-term.
Photo of Matt BaraschMatt BaraschUnlock Rating
$29.55

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Aug 18, 2003
(A top pick July 23/03.Down 4 «%.)Drug companies , stocks have dropped because they think of concerns on drug pricing.Longer-term demographically Phizer is very well-positioned.It represents great long-term value.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$31.47

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Aug 12, 2003
Model price is around $29.Prefers Merk.Too expensive.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$32.87

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Aug 07, 2003
Likes this company.Valuation is more attractive than what it has been for some time.Generating growth, and very little risk in the stock.
Photo of John ZechnerJohn Zechner
Owned
Unlock Rating
$32.94

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 24, 2003
Good company. Pharmaceutical group is reasonably well priced. Compatition is coming into their core product line.
Photo of Ian AinsworthIan Ainsworth
Owned
Unlock Rating
$32.55

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 23, 2003
15/25% earnings growth for the next 3/5 years. High quality.
Photo of Laura WallaceLaura Wallace
Owned
Unlock Rating
$32.93

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jul 22, 2003
Ethical drug companies are not doing well at this time.
Photo of David BurrowsDavid Burrows
No
Unlock Rating
$32.43

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
WEAK BUY

Pfizer Inc(PFE)

Jul 17, 2003
Has the deepest and broadest portfolio of any drug company. 20 drugs under development. Growth may be limited.
Photo of Brad WillockBrad Willock
Owned
Unlock Rating
$32.76

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 15, 2003
Has a huge pipeline. PE is at a reasonable level. Good dividends and they are increasing.
Photo of Bob StodgellBob Stodgell
Owned
Unlock Rating
$33.86

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Jul 10, 2003
Fair market value is excellant. Investors like drug stocks.
Photo of Ross HealyRoss HealyUnlock Rating
$33.66

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Jul 02, 2003
If you own it, don't let it make new lows on you. Trend is moving higher.
Photo of Bill CarriganBill CarriganUnlock Rating
$34.65

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 766 to 780 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BUG 4.44$44.48
GS -40.73$988.45
NFLX 2.92$80.32
DAL -0.11$79.8
DML.TO -0.16$4.03

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79

Most Recent Experts

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like